Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46

Deutsche Bank analyst David Hoang has downgraded Xenon Pharmaceuticals (NASDAQ: XENE) from a Buy rating to Hold. The price target for the stock has been reduced significantly from $90 to $46.